CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of RNA interference (RNAi) therapeutics, today announced that the Company has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI), effective upon market open on December 21, 2015.
The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market® that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. These companies must meet eligibility requirements, including minimum market capitalization, average daily trading volume, and seasoning as a public company, among other criteria. For more information about the NASDAQ Biotechnology Index visit www.nasdaq.com.
The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market® that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. These companies must meet eligibility requirements, including minimum market capitalization, average daily trading volume, and seasoning as a public company, among other criteria. For more information about the NASDAQ Biotechnology Index visit www.nasdaq.com.
